PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681331
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681331
Global Biomarker Discovery Outsourcing Services Market Size Study, By Biomarker Type, By Therapeutic Area, By Discovery Phase, By End Use, and Regional Forecasts 2022-2032
The global biomarker discovery outsourcing services market is valued at approximately USD 12.17 billion in 2023 and is projected to grow with a healthy CAGR of 19.4% over the forecast period 2024-2032. Biomarkers play an essential role in disease diagnosis, prognosis, and therapeutic monitoring, fueling their increasing demand across pharmaceutical and biotechnology industries. The market is experiencing significant growth due to technological advancements in omics technologies (genomics, proteomics, metabolomics), artificial intelligence (AI), and machine learning (ML)-driven biomarker identification. Moreover, the growing adoption of personalized medicine, the rising prevalence of chronic diseases, and the need for high-throughput biomarker discovery solutions are further fueling the outsourcing demand.
The pharmaceutical and biotech industries are increasingly outsourcing biomarker research to contract research organizations (CROs) due to cost efficiency, faster drug development timelines, and access to specialized expertise. AI-powered predictive biomarker discovery, multi-omics integration, and growing strategic collaborations between pharma companies and CROs are reshaping the industry landscape. Furthermore, government initiatives and regulatory agency support for biomarker-based clinical trials, particularly from the U.S. FDA, EMA, and ICH, are driving investment in biomarker validation and accelerating market expansion.
The expansion of R&D investments in biopharmaceuticals is another significant factor propelling market growth. With increasing drug development complexities and the shift toward biologics and cell & gene therapies, pharmaceutical companies are allocating larger budgets to biomarker-driven research. This trend has resulted in a surge in industry-academia partnerships, venture capital funding, and government-backed research programs to facilitate biomarker discovery. In addition, the development of non-invasive liquid biopsy biomarkers and digital pathology solutions is enhancing the efficiency of biomarker-based diagnostics. The integration of AI-driven predictive analytics, real-world data, and automation in biomarker discovery further enhances the role of outsourcing in optimizing biopharmaceutical R&D pipelines and improving drug success rates.
As cost efficiency and regulatory compliance become key priorities, outsourcing to specialized CROs and contract development and manufacturing organizations (CDMOs) has emerged as a strategic approach in the biomarker discovery space. These service providers offer end-to-end biomarker discovery solutions, including early-stage biomarker validation, preclinical and clinical validation, and regulatory compliance support, thereby accelerating time-to-market. The market is also witnessing increasing acquisitions, partnerships, and geographic expansions by CROs to meet the rising demand for biomarker discovery services. Additionally, automation in biomarker analysis, cloud-based bioinformatics, and decentralized clinical trials are playing a vital role in shaping future market dynamics.
Major Market Players Included in this Report are:
- LabCorp
- Charles River Laboratories International, Inc.
- Eurofins Scientific
- Celerion
- ICON plc
- Parexel International (MA) Corporation
- Proteome Sciences
- GHO Capital
- Thermo Fisher Scientific Inc.
- Evotec
The Detailed Segments and Sub-Segment of the Market are Explained Below:
By Biomarker Type:
By Therapeutic Area:
By Discovery Phase:
By End Use:
By Region:
North America:
Europe:
Asia Pacific:
Latin America:
Middle East & Africa:
Years Considered for the Study are as follows:
Key Takeaways:
Table of Contents
Chapter 1. Global Biomarker Discovery Outsourcing Services Market Executive Summary
- 1.1. Global Biomarker Discovery Outsourcing Services Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Biomarker Type
- 1.3.2. By Therapeutic Area
- 1.3.3. By Discovery Phase
- 1.3.4. By End Use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Biomarker Discovery Outsourcing Services Market Definition and Research Assumptions
Chapter 3. Global Biomarker Discovery Outsourcing Services Market Dynamics
Chapter 4. Global Biomarker Discovery Outsourcing Services Market Industry Analysis
Chapter 5. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Biomarker Type (2022-2032)
Chapter 6. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Therapeutic Area (2022-2032)
Chapter 7. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Discovery Phase (2022-2032)
Chapter 8. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by End Use (2022-2032)
Chapter 9. Global Biomarker Discovery Outsourcing Services Market Size & Forecasts by Region (2022-2032)
Chapter 10. Competitive Intelligence
Chapter 11. Research Process
